BeyondSpring (BYSI.us) was founded in 2013 and is headquartered in the United States. The company is a global clinical-stage biopharmaceutical company focused on novel cancer therapies, including the development of advanced oncology immuno-oncology drugs. On March 9, 2017, BeyondSpring was listed on the NASDAQ. Efung Capital invested in the company in 2019.